Study of VOY-101 for advanced dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial is testing a new treatment called VOY-101 for people with advanced dry age-related macular degeneration (geographic atrophy). It aims to see if the drug can slow or stop vision loss in this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years old or older.
- You must have geographic atrophy (advanced dry AMD) in both eyes, with no history of wet AMD.
- You must meet certain genetic risk criteria for AMD (this will be tested).
- You must be willing to come to all study visits and have eye exams and imaging.
- If you are a woman who could become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This study follows up with people who already received the VOY-101 injection for a type of age-related vision loss (non-neovascular age-related macular degeneration) in an earlier study. It checks how they are doing over a longer period of time.
This trial tests an oral medication called BRX011 for people with geographic atrophy (a form of advanced dry age-related macular degeneration). The goal is to see if it is safe and can help slow vision loss.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.